The 2024 Medtech Big 100 ranks the world’s largest medical device companies by revenue. [Illustration by Matthew Claney/Medical Design & Outsourcing]Medtronic remains at the top, but Johnson & Johnson MedTech is now a close second in the Medtech Big 100 list of largest medical device companies.

2024年Medtech 100强按收入排名世界最大的医疗器械公司。[Matthew Claney/Medical Design&Outsourcing插画]美敦力（Medtronic）仍然位居榜首，但强生医疗科技（Johnson&Johnson MedTech）目前在美敦力（MedTech）100家最大医疗器械公司中排名第二。

Could we see a new No. 1 company in next year’s Medtech Big 100 report? Time will tell. But in the meantime, this year’s edition of Medical Design & Outsourcing and MassDevice‘s Medtech Big 100 is chock-full of insights about the 100 largest medical device companies in the world.

我们能否在明年的Medtech Big 100报告中看到一家新的排名第一的公司？时间会证明一切的。。

Managing Editor Jim Hammerand and Senior Editor Danielle Kirsh’s analysis found that a wave of mergers and acquisitions made the world’s largest medical device companies even larger. Even amid some layoffs and belt-tightening, M&A grew overall sales to a record-high $474.8 billion year-over-year among the 100 largest companies.

总编辑吉姆·哈默兰德（JimHammerand）和高级编辑丹妮尔·柯什（DanielleKirsh）的分析发现，一波并购浪潮使世界上最大的医疗器械公司规模更大。即便在一些裁员和勒紧裤腰带的情况下，在100家最大的公司中，并购的总销售额同比增长至创纪录的4748亿美元。

(Read the full story on MDO.).

（阅读MDO的完整故事）。

The Medtech Big 100 includes annual revenue, R&D spending, headcount, CEOs and key leaders, headquarters locations and descriptions of each company. We collect data from regulatory disclosures filed with the SEC and annual reports from foreign and privately held firms. For many companies, we include data they share with us..

Medtech Big 100包括年度收入、研发支出、员工总数、首席执行官和关键领导者、总部地点和每家公司的描述。我们从向SEC提交的监管披露以及外国和私人控股公司的年度报告中收集数据。对于许多公司来说，我们包括他们与我们共享的数据。。

Read the full Medtech Big 100 report to find out more about the 100 largest medical device companies.

阅读完整的Medtech Big 100报告，了解有关100家最大医疗器械公司的更多信息。

Here are the 10 largest medtech companies by revenue:

以下是收入最大的10家医疗科技公司：

Company

公司

Annual Revenue

年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入，年收入

Medtronic

美敦力

$32.4B

324亿美元

Johnson & Johnson MedTech

强生医疗技术公司

$30.4B

304亿美元

Siemens Healthineers

西门子Healthineers

$23.4B

234亿美元

Medline Industries

Medline工业

$23.2B

232亿美元

Stryker

史崔克

$20.5B

205亿美元

Philips

飞利浦

$19.6B

196亿美元

GE HealthCare

GE HealthCare

$19.6B

196亿美元

Abbott (medical device segment)

雅培（医疗器械板块）

$16.9B

169亿美元

Cardinal Health (medical segment)

Cardinal Health（医疗部分）

$15.0B

150亿美元

Baxter

巴克斯特

$14.8B

148亿美元

And here is more about the 10 largest medical device companies:

以下是关于10家最大医疗器械公司的更多信息：

1. Medtronic

1、美敦力

“Our top priority is restoring our earnings power — full stop,” Medtronic Chair and CEO Geoff Martha said to start 2024. Over the following months, the world’s largest medtech company continued significant portfolio management moves, including the shuttering of its ventilators business. There was more discipline on headcount and expenses — including worldwide layoffs — and increased use of automation and digitization.

美敦力董事长兼首席执行官杰夫·玛莎（GeoffMartha）表示，从2024年开始，“我们的首要任务是恢复盈利能力-句号。”。在接下来的几个月里，这家全球最大的医疗科技公司继续进行重大的投资组合管理行动，包括关闭其呼吸机业务。在员工人数和费用方面有了更多的纪律，包括全球范围的裁员，自动化和数字化的使用也有所增加。

Some high-ranking officials have left the company, too — including CFO Karen Parkhill, who resigned to take over as CFO at HP. At the same time, company leaders stressed that Medtronic is making strategic investments in research and development to boost future growth. They said in May that the company had achieved 130 product approvals in the last 12 months in key geographies.

一些高级官员也离开了公司，包括首席财务官凯伦·帕克希尔（KarenParkhill），后者辞去了惠普首席财务官的职务。与此同时，公司领导强调，美敦力正在对研发进行战略投资，以促进未来的增长。他们在5月份表示，该公司在过去12个月内在关键地区获得了130个产品批准。

Recent wins include:.

最近的胜利包括：。

The PulseSelect pulsed field ablation system becoming the first PFA system approved by the FDA to treat paroxysmal and persistent atrial fibrillation (AFib);

PulseSelect脉冲场消融系统成为FDA批准用于治疗阵发性和持续性心房颤动（AFib）的第一个PFA系统；

FDA approval of the next-generation Evolut FX+ transcatheter aortic valve replacement (TAVR) system;

FDA批准下一代Evolut FX+经导管主动脉瓣置换术（TAVR）系统；

FDA approval of its Percept RC deep brain stimulation system, which Medtronic described as the first DBS sensing-enabled, rechargeable device to treat movement disorders such as Parkinson’s disease;

FDA批准其Percept RC深部脑刺激系统，美敦力将其描述为第一个DBS传感可充电设备，用于治疗帕金森氏病等运动障碍；

And the launch of the next-gen Micra AV2 and Micra VR2 leadless pacemakers, which were approved in 2023.

下一代Micra AV2和Micra VR2无铅起搏器于2023年获得批准。

Medtronic is also seeking coverage and payments for its FDA-approved Simplicity Spyral renal denervation technology to treat hypertension. In August, it secured a CMS New Technology Add-on Payment (NTAP) win for the technology.

美敦力（Medtronic）也在为其FDA批准的用于治疗高血压的Simplicity Spyral肾脏去神经支配技术寻求保险和付款。8月，该公司获得了该技术的CMS新技术附加支付（NTAP）胜利。

Medtronic is projecting 4–5% organic revenue growth in 2024.

美敦力预计2024年有机收入将增长4-5%。

MORE ON MDO: AI basics from Medtronic Chief Technology and Innovation Officer Ken Washington

有关MDO的更多信息：美敦力首席技术和创新官肯·华盛顿（KenWashington）的AI基础知识

2. Johnson & Johnson MedTech

强生医疗技术公司

Now under the leadership of Johnson & Johnson veteran Tim Schmid after Ashley McEvoy’s announcement in October 2023 that she was resigning, Johnson & Johnson MedTech continues to grow. With its $13 billion acquisition of Shockwave Medical and its intravascular lithotripsy (IVL) technology completed in May, J&J’s medical device business could give Medtronic a run for the top spot in next year’s Medtech Big 100.

在AshleyMcEvoy于2023年10月宣布辞职后，现在在强生老兵TimSchmid的领导下，强生医疗技术公司继续发展。随着其斥资130亿美元收购Shockwave Medical及其血管内碎石术（IVL）技术于5月份完成，强生的医疗器械业务可能会让美敦力在明年的Medtech Big 100中夺得榜首。

On top of the Shockwave acquisition, recent developments at J&J MedTech include the unveiling of Polyphonic, its open and secure digital surgical ecosystem. Think data-source-agnostic software applications to deliver surgical insights. The first release included apps for surgical video, telepresence and planning.

除了收购Shockwave之外，强生医疗科技（J＆J MedTech）的最新发展包括推出Polyphonic，其开放且安全的数字手术生态系统。思考数据源不可知的软件应用程序，以提供手术见解。第一个版本包括用于手术视频、远程临场感和计划的应用程序。

Watch for more artificial intelligence applications created through a partnership with Nvidia that the companies announced in March. Other recent J&J MedTech news includes:.

期待更多的人工智能应用程序通过与Nvidia的合作创建，这两家公司在3月份宣布。强生医疗科技最近的其他新闻包括：。

Its DePuy Synthes business has launched a spine surgery version of its Velys robot, created in collaboration with eCential Robotics.

其DePuy Synthes业务推出了与eCential Robotics合作开发的Velys机器人脊柱手术版本。

In April, the company sold its Ethicon business’ Acclarent ear, nose and throat treatment tech business to Integra LifeSciences for $275 million.

4月，该公司以2.75亿美元将其Ethicon业务备受赞誉的耳鼻喉治疗技术业务出售给Integra LifeSciences。

J&J MedTech expects to submit its Ottava surgical robot for FDA investigational device exemption (IDE) in the second half of 2024.

强生医疗技术公司预计在2024年下半年将其Ottava手术机器人提交给FDA研究设备豁免（IDE）。

Its Biosense Webster business has submitted its AFib-treating Varipulse pulsed field ablation system for FDA approval.

其Biosense Webster业务已将其AFib治疗Varipulse脉冲场消融系统提交FDA批准。

J&J MedTech has a deal to buy cardiac implant developer V-Wave for up to $1.7 billion.

强生医疗技术公司（J＆J MedTech）已达成协议，以高达17亿美元的价格收购心脏植入物开发商V-Wave。

Johnson & Johnson CEO Joaquin Duato spoke in July of the company having a “strong foundation for near and long-term growth.”

强生公司首席执行官华金·杜阿托（JoaquinDuato）在7月份表示，该公司拥有“强大的近期和长期增长基础”

MORE ON MDO: High voltage in the heart: PFA catheter design tips from Biosense Webster

更多关于MDO：心脏中的高电压：Biosense Webster的PFA导管设计技巧

3. Siemens Healthineers

3、西门子Healthineers

Siemens Healthineers reported good progress in its third quarter despite ongoing order delays in China. The German medtech giant now expects 4.5–6.5% sales growth for fiscal 2024. “Varian and Diagnostics especially contributed to the strong operating performance,” CEO Bernd Montag said in late July.

西门子Healthineers报告称，尽管在中国的订单持续延迟，但第三季度取得了良好进展。这家德国医疗科技巨头目前预计2024财年销售额将增长4.5-6.5%。首席执行官伯纳德·蒙塔格（BerndMontag）在7月底表示：“瓦里安（Varian）和诊断公司（Diagnostics）尤其为强劲的经营业绩做出了贡献。”。

Recent innovations at the company include the FDA-cleared Syngo Virtual Cockpit, a platform that enables real-time collaboration between healthcare professionals across different locations​​. The FDA also cleared the Magnetom Cima.X 3 Tesla (3T) magnetic resonance imaging whole-body scanner. The company said that scanner has the strongest gradients ever for a whole-body scanner, which improve the visibility of smaller structures and accelerates image captures.

该公司最近的创新包括FDA批准的Syngo虚拟驾驶舱，该平台可实现不同地点医疗保健专业人员之间的实时协作。FDA还批准了Magnetom Cima。X 3特斯拉（3T）磁共振成像全身扫描仪。该公司表示，扫描仪具有全身扫描仪有史以来最强的梯度，可以提高较小结构的可见度并加速图像捕获。

Additionally, Siemens Healthineers announced in March that its self-driving Ciartic Move mobile C-arm received an FDA clearance. Ciartic Move automates and accelerates imaging workflows in surgical environments​. Meanwhile, Varian in March announced clearance of its TrueBeam and Edge radiotherapy systems with HyperSight imaging..

此外，西门子Healthineers于3月宣布，其自动驾驶Ciartic Move mobile C-arm已获得FDA批准。Ciartic Move自动化并加速了手术环境中的成像工作流程。与此同时，瓦里安公司（Varian）于3月份宣布，其TrueBeam和Edge放射治疗系统将通过HyperSight成像技术获得许可。。

4. Medline Industries

4、Medline行业

Medline revenue grew 9% in 2023. The privately-held medical supply manufacturer, distributor and services provider now operates in over 100 countries and territories, offering more than 335,000 medical products. Medline recently grew even more through its $950 million acquisition of Ecolab’s surgical solutions business.

2023年，Medline收入增长了9%。这家私营医疗用品制造商、分销商和服务提供商目前在100多个国家和地区运营，提供335000多种医疗产品。Medline最近以9.5亿美元收购了Ecolab的外科解决方案业务，从而实现了更大的增长。

The deal gave Medline access to operating room equipment, Ecolab’s line of Microtek sterile operating room drapes and Ecolab’s fluid temperature management system. “With this acquisition, we are eager to collaborate with healthcare providers and cutting-edge medical device companies to bring innovative solutions to the surgical suite,” Medline President and Chief Operating Officer Jim Pigott said.

该协议使Medline能够使用手术室设备、Ecolab的Microtek无菌手术室窗帘系列和Ecolab的液体温度管理系统。Medline总裁兼首席运营官吉姆·皮戈特（JimPigott）表示：“通过此次收购，我们渴望与医疗保健提供商和尖端医疗器械公司合作，为手术室带来创新的解决方案。”。

Medline recently spent $27 million to triple the size of its product testing and development lab in Mundelein, Illinois, to 74,000 ft²..

Medline最近花费了2700万美元，将其位于伊利诺伊州蒙代林的产品测试和开发实验室规模扩大了三倍，达到74000平方英尺。。

5. Stryker

5、史崔克

Still riding the success of its Mako robotic orthopedic surgery systems and digital surgery systems, Stryker has gone on offense with M&A. Recent tuck-in acquisitions for the orthopedic and surgical tech giant include Artelon and its soft tissue fixation products for foot and ankle and sports medicine procedures, and Molli Surgical, which develops wire-free soft tissue localization technology for breast-conserving surgery.

尽管凭借其Mako机器人骨科手术系统和数字手术系统的成功，史崔克仍在通过并购发起进攻。这家骨科和外科技术巨头最近的收购包括Artelon及其用于足踝和运动医学手术的软组织固定产品，以及Molli surgical，该公司开发了用于保乳手术的无线软组织定位技术。

Stryker Chair and CEO Kevin Lobo recently indicated that the company has a very active deal pipeline for even more M&A. He said a soft-tissue surgical robotics play is a possibility, as well something in the neuromodulation space down the road. Notable updates include the myMako app for Apple Vision Pro, which enhances surgeons’ ability to visualize and plan surgeries.

Stryker主席兼首席执行官凯文·洛博（KevinLobo）最近表示，该公司有一个非常积极的交易渠道，可以进行更多的并购。他说，软组织手术机器人是一种可能，也是未来神经调节领域的一种可能。值得注意的更新包括Apple Vision Pro的myMako应用程序，它增强了外科医生可视化和计划手术的能力。

Stryker also introduced the Triathlon Hinge within its knee surgery offerings, aiming to simplify revision procedures​. Analysts expect Stryker to enjoy even more growth on shoulder and spine applications for Mako that are slated for later this year..

史崔克还在其膝关节手术产品中引入了三项全能铰链，旨在简化翻修程序。分析人士预计，史崔克将在今年晚些时候为Mako提供更多的肩部和脊柱应用。。

MORE ON MDO: How 3D printing and surgical robotics enable Stryker’s cementless knee implants

关于MDO的更多信息：3D打印和手术机器人如何实现Stryker的非骨水泥膝关节植入物

6. Philips

6、飞利浦

The fallout from Philips’ massive, yearslong recall of CPAPs and other respiratory devices reached a critical point in 2024. In April, the Dutch medtech giant finalized a consent decree with the U.S. Department of Justice and FDA that provided a roadmap for resolving the Philips Respironics recall. Dr.

飞利浦长达一年的大规模CPAP和其他呼吸设备召回的影响在2024年达到了关键点。4月，这家荷兰医疗科技巨头与美国司法部和FDA达成了一项同意令，为解决飞利浦Respironics召回事件提供了路线图。博士。

Jeff Shuren, who was director of the FDA’s Center for Devices and Radiological Health (CDRH) at the time, said the agreement “marks the first time a device company is providing a remediation payment option for a recalled device under a consent decree.” Philips soon settled personal injury claims in the U.S.

杰夫·舒伦（Jeff Shuren）当时是美国食品和药物管理局（FDA）设备与放射健康中心（CDRH）的主任，他说，该协议“标志着设备公司首次根据许可令为召回的设备提供补救付款选择。”飞利浦很快就美国的人身伤害索赔达成和解。

for $1.1 billion and is also paying at least $613 million to settle personal injury claims. By June, Philips announced the closure of its Respironics business’ Pittsburgh headquarters and elimination of hundreds of manufacturing jobs in the region. Exclude the impact of the Respironics recall, however, and Philips is still projecting 3–5% comparable sales growth in 2024.

支付11亿美元，并支付至少6.13亿美元以解决人身伤害索赔。6月，飞利浦宣布关闭其Respironics业务匹兹堡总部，并取消该地区数百个制造业岗位。然而，排除Respironics召回的影响，飞利浦仍预计2024年可比销售额增长3-5%。

Said CEO Roy Jakobs: “We continue to focus on enhancing execution, improving end-to-end supply chain resilience and increasing agility and productivity through simplifying our operating model. Patient safety and quality remains our number one priority.”.

首席执行官罗伊·雅各布斯（RoyJakobs）表示：“我们继续专注于提高执行力，通过简化运营模式提高端到端供应链的弹性，提高灵活性和生产力。患者安全和质量仍然是我们的首要任务。”。

7. GE HealthCare

7、GE HealthCare

GE HealthCare is facing headwinds in the market in China, which caused it in July to reduce its organic revenue growth projection to 1–2%, versus the previous projection of 4%. CEO Peter Arduini highlighted year-over-year sales growth and margin expansion in the second quarter: “We are pleased with our continued progress in advancing our margin goals, while continuing our investments for future growth.” GE HealthCare continues with new partnerships, products and tuck-in acquisitions, especially when it comes to medtech innovations enabled by artificial intelligence.

通用电气医疗保健（GE HealthCare）在中国市场面临阻力，这导致它在7月份将其有机收入增长预测降至1-2%，而之前的预测为4%。首席执行官彼得·阿杜伊尼（PeterArduini）强调了第二季度销售额的同比增长和利润率的扩大：“我们对我们在推进利润率目标方面取得的持续进展感到高兴，同时继续为未来的增长进行投资。”通用电气医疗保健公司继续进行新的合作伙伴关系、产品和收购，特别是在人工智能支持的医疗技术创新方面。

Recent AI-related moves include:.

最近与人工智能相关的举措包括：。

A joint development agreement with Volta Medical over AI-driven electrophysiology tech;

与Volta Medical就AI驱动的电生理技术达成联合开发协议；

Acquiring Intelligent Ultrasound Group’s clinical AI software business;

收购智能超声集团的临床AI软件业务；

The launch of the AI-enhanced Voluson Signature 20 and 18 ultrasound systems for women’s health imaging applications;

推出AI增强型Voluson Signature 20和18超声波系统，用于女性健康成像应用；

A partnership with Biofourmis to use its FDA-cleared, AI-guided algorithms to help deliver personalized healthcare and health monitoring in people’s homes.

与Biofourmis合作，使用FDA批准的人工智能引导算法，帮助在人们的家中提供个性化的医疗保健和健康监测。

In addition, GE HealthCare in May announced the launch of its “new era” of AI-enhanced oncology solutions, known as Revolution RT.

此外，GE HealthCare于5月宣布推出其人工智能增强肿瘤学解决方案的“新时代”，称为Revolution RT。

8. Abbott (medical device segment)

8、雅培（医疗器械板块）

Abbott medical device segment sales were up more than 12% during the first half of 2024. Diabetes treatment tech — especially the Abbott FreeStyle Libre continuous glucose monitor (CGM) — played an important role fueling the growth. FreeStyle Libre sales totaled $1.6 billion in the second quarter alone, marking 18.4% growth year-over-year.

2024年上半年，雅培医疗器械部门的销售额增长了12%以上。糖尿病治疗技术，尤其是雅培自由泳连续血糖监测仪（CGM），在促进糖尿病患者的生长方面发挥了重要作用。仅在第二季度，FreeStyle Libre的销售额就达到16亿美元，同比增长18.4%。

A new partnership to combine FreeStyle Libre CGM technology with Medtronic’s automated insulin delivery systems could boost sales even more in the years ahead. In June, Abbott announced that it secured FDA clearance for two over-the-counter CGM systems, Lingo and Libre Rio. Electrophysiology is also an exciting space for Abbott.

将FreeStyle Libre CGM技术与美敦力的自动胰岛素输送系统相结合的新合作伙伴关系可能会在未来几年进一步推动销售。6月，雅培宣布获得FDA对两种非处方CGM系统Lingo和Libre Rio的批准。电生理学对雅培来说也是一个令人兴奋的领域。

The company in June announced CE mark approval for its Aveir DR dual-chamber leadless pacemaker system, nearly a year after Aveir won FDA approval. The company has seen recent launches and new indications for its Amplatzer Amulet, Navitor, and TriClip. When it comes to pulsed field ablation, Abbott continues to develop its Volt system, which has a ​​balloon-in-basket design meant to enable efficient deployment of energy into the tissue during cardiac ablation to treat AFib..

该公司于6月宣布其Aveir DR双腔无铅起搏器系统获得CE标志批准，距离Aveir获得FDA批准将近一年。该公司最近推出了Amplatzer护身符、Navitor和TriClip，并有了新的迹象。谈到脉冲场消融，雅培继续开发其Volt系统，该系统具有球囊篮式设计，旨在在心脏消融治疗AFib期间将能量有效部署到组织中。。

MORE ON MDO: Abbott bets on balloons in pulsed field ablation battle

关于MDO的更多信息：雅培在脉冲场消融战中押注气球

9. Cardinal Health (medical segment)

9、Cardinal Health（医疗板块）

During Cardinal Health’s third-quarter earnings call on May 2, CEO Jason Hollar reported that the company’s Global Medical Products and Distribution (GMPD) business is seeing strong topline and bottom line performance, with growth accelerating as a turnaround plan accelerates. “GMPD’s quarter was overall consistent with our expectations and the team is already working hard on the continued ramp-up in Q4,” Hollar said.

在5月2日红衣主教健康公司（Cardinal Health）第三季度财报电话会议上，首席执行官杰森·霍拉（Jason Hollar）报告称，该公司的全球医疗产品和分销（GMPD）业务表现强劲，随着周转计划的加快，增长速度加快。霍拉尔说：“GMPD的季度总体上符合我们的预期，团队已经在努力争取第四季度的持续增长。”。

Cardinal Health said its U.S. Medical Products and Distribution Business won recognition from the HIRC Resiliency Badge program for its supply chain resiliency..

Cardinal Health表示，其美国医疗产品和分销业务因其供应链弹性而获得了HIRC弹性徽章计划的认可。。

10. Baxter

10、巴克斯特

Baxter continues to move forward with a separation of its Kidney Care business, which will be called Vantive. In mid-August it announced that it would sell Vantive to global investment firm Carlyle for $3.8 billion. The companies expect the transaction to close in late 2024 or early 2025, subject to customary approvals and closing conditions.

巴克斯特继续推进其肾脏护理业务的分离，这将被称为Vantive。8月中旬，该公司宣布将以38亿美元的价格将Vantive出售给全球投资公司凯雷（Carlyle）。这些公司预计该交易将在2024年末或2025年初结束，但须遵守惯例批准和结束条件。

“As a result of this proposed transaction, Baxter will emerge a more focused and more efficient company, better positioned to redefine healthcare delivery and advance innovation that benefits patients, customers and shareholders,” Baxter Chair and CEO José Almeida said. Meanwhile, the Baxter Medical Products & Therapies business has benefitted from positive pricing and demand.

巴克斯特董事长兼首席执行官何塞·阿尔梅达（JoséAlmeida）表示：“此次拟议交易的结果是，巴克斯特将成为一家专注度更高、效率更高的公司，能够更好地重新定义医疗服务，推进创新，造福患者、客户和股东。”。与此同时，巴克斯特医疗产品和疗法业务受益于积极的定价和需求。

The second quarter also saw the first U.S. sales of the Novum IQ large-volume infusion pump with Dose IQ safety software..

第二季度，Novum IQ大容量输液泵首次在美国销售，该泵配有Dose IQ安全软件。。

Here is our 10 largest medical device companies list from last year.

这是我们去年的十大医疗器械公司名单。

Read the full Medtech Big 100 report about the world’s largest medical device companies.

阅读有关世界最大医疗器械公司的完整Medtech Big 100报告。

And here’s the 2023 report.

这是2023年的报告。

And here’s the 2022 report.

这是2022年的报告。

And here’s the 2021 report.

这是2021年的报告。